drugset / Trial / NCT02558374

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

NCT02558374

Phase 3 Completed 708 enrolled Aerie Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.

Timeline

Start
2015-09
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Netarsudil Small molecule 0.02 % Other
Comparator Timolol Other / unclassified 0.5 % Other